A systematic review and meta-analysis. J Card Surg. 2013;28:109 116. doi: 10.1111/jocs.12074. 45. de Leon N, Jackevicius CA. Use of aspirin and clopidogrel after coronary artery bypass graft surgery. Ann Pharmacother. 2012;46:678 687. doi: 10.1345/aph.1Q692. 46. Nocerino AG, Achenbach S, Taylor AJ. Meta-analysis of effect of single versus dual antiplatelet therapy on early patency of bypass conduits after coronary artery bypass grafting. Am J Cardiol. 2013;112:1576 1579. doi: 10.1016/j.amjcard.2013.07.017. 47. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001 2015. doi: 10.1056/ NEJMoa0706482. 48. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA; PLATO Investigators, Freij A, Thors n M. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045 1057. doi: 10.1056/ NEJMoa0904327. 49. Held C, Asenblad N, Bassand JP, Becker RC, Cannon CP, Claeys MJ, Harrington RA, Horrow J, Husted S, James SK, Mahaffey KW, Nicolau JC, Scirica BM, Storey RF, Vintila M, Ycas J, Wallentin L. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergo- ing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. J Am Coll Cardiol. 2011;57:672 684. doi: 10.1016/j.jacc.2010.10.029. 50. Smith PK, Goodnough LT, Levy JH, Poston RS, Short MA, Weerakkody GJ, Lenarz LA. Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospec- tive data analysis. J Am Coll Cardiol. 2012;60:388 396. doi: 10.1016/j. jacc.2012.03.030. 51. Varenhorst C, Alstr m U, Scirica BM, Hogue CW, senblad N, Storey RF, Steg PG, Horrow J, Mahaffey KW, Becker RC, James S, Cannon CP, Brandrup-Wognsen G, Wallentin L, Held C. Factors contribut- ing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgery. J Am Coll Cardiol. 2012;60:1623 1630. doi: 10.1016/j.jacc.2012.07.021. 52. Mariani MA, Gu YJ, Boonstra PW, Grandjean JG, van Oeveren W, Ebels T. Procoagulant activity after off-pump coronary operation: is the current anticoagulation adequate? Ann Thorac Surg. 1999;67:1370 1375. 53. Kim KB, Lim C, Lee C, Chae IH, Oh BH, Lee MM, Park YB. Off-pump coronary artery bypass may decrease the patency of saphenous vein grafts. Ann Thorac Surg. 2001;72:S1033 S1037. 54. Casati V, Gerli C, Franco A, Della Valle P, Benussi S, Alfieri O, Torri G, D Angelo A. Activation of coagulation and fibrinolysis during coro- nary surgery: on-pump versus off-pump techniques. Anesthesiology. 2001;95:1103 1109. 55. Kurlansky PA. Is there a hypercoagulable state after off-pump coronary artery bypass surgery? What do we know and what can we do? J Thorac Cardiovasc Surg. 2003;126:7 10. 56. Bidstrup BP, Scarrott H, Luque M. Platelet function after off pump coro- nary surgery. Heart Surg Forum. 2003;6:286 287. 57. Quigley RL, Fried DW, Pym J, Highbloom RY. Off-pump coronary artery bypass surgery may produce a hypercoagulable patient. Heart Surg Forum. 2003;6:94 98. 58. Poston R, Gu J, Manchio J, Lee A, Brown J, Gammie J, White C, Griffith BP. Platelet function tests predict bleeding and thrombotic events after off- pump coronary bypass grafting. Eur J Cardiothorac Surg. 2005;27:584 591. doi: 10.1016/j.ejcts.2004.12.061. 59. Bednar F, Osmancik P, Vanek T, Mocikova H, Jares M, Straka Z, Widimsky P. Platelet activity and aspirin efficacy after off-pump compared with on-pump coronary artery bypass surgery: results from the prospective randomized trial PRAGUE 11-Coronary Artery Bypass and REactivity of Thrombocytes (CABARET). J Thorac Cardiovasc Surg. 2008;136:1054 1060. doi: 10.1016/j.jtcvs.2008.03.052. 60. Wang Z, Gao F, Men J, Ren J, Modi P, Wei M. Aspirin resistance in off-pump coronary artery bypass grafting. Eur J Cardiothorac Surg. 2012;41:108 112. doi: 10.1016/j.ejcts.2011.04.021. 61. Gundry SR, Romano MA, Shattuck OH, Razzouk AJ, Bailey LL. Seven-year follow-up of coronary artery bypasses performed with and without cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1998;115: 1273 1277. 62. Puskas JD, Williams WH, Mahoney EM, Huber PR, Block PC, Duke PG, Staples JR, Glas KE, Marshall JJ, Leimbach ME, McCall SA, Petersen RJ, Bailey DE, Weintraub WS, Guyton RA. Off-pump vs conventional coronary artery bypass grafting: early and 1-year graft patency, cost, and quality-of-life outcomes: a randomized trial. JAMA. 2004;291:1841 1849. doi: 10.1001/jama.291.15.1841. Kulik et al Secondary Prevention After CABG 953 63. Ibrahim K, Tjomsland O, Halvorsen D, Wiseth R, Wahba A, Karevold A, Haaverstad R. Effect of clopidogrel on midterm graft patency fol- lowing off-pump coronary revascularization surgery. Heart Surg Forum. 2006;9:E581 E856. doi: 10.1532/HSF98.20061034. 64. Gurbuz AT, Zia AA, Vuran AC, Cui H, Aytac A. Postoperative clopidogrel improves mid-term outcome after off-pump coronary artery bypass graft surgery: a prospective study. Eur J Cardiothorac Surg. 2006;29:190 195. doi: 10.1016/j.ejcts.2005.11.033. 65. Nielsen AB, Bochsen L, Steinbr chel DA. Hypercoagulability and platelet inhibition after OPCAB: randomized intervention with clopidogrel. Scand Cardiovasc J. 2007;41:325 330. doi: 10.1080/14017430701383763. 66. Mannacio VA, Di Tommaso L, Antignan A, De Amicis V, Vosa C. Aspirin plus clopidogrel for optimal platelet inhibition following off-pump coronary artery bypass surgery: results from the CRYSSA (prevention of Coronary arteRY bypaSS occlusion After off-pump procedures) randomised study. Heart. 2012;98:1710 1715. doi: 10.1136/heartjnl-2012-302449. 67. Gohlke H, Gohlke-B rwolf C, St rzenhofecker P, G rnandt L, Ritter B, Reichelt M, Buchwalsky R, Schmuziger M, Roskamm H. Improved graft patency with anticoagulant therapy after aortocoronary bypass surgery: a prospective, randomized study. Circulation. 1981;64(pt 2):II22 II27. 68. Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low- dose anticoagulation on obstructive changes in saphenous-vein coronary- artery bypass grafts. N Engl J Med. 1997;336:153 162. 69. Wann LS, Curtis AB, January CT, Ellenbogen KA, Lowe JE, Estes NA 3rd, Page RL, Ezekowitz MD, Slotwiner DJ, Jackman WM, Stevenson WG, Tracy CM, Fuster V, Ryd n LE, Cannom DS, Le Heuzey JY, Crijns HJ, Lowe JE, Curtis AB, Olsson S, Ellenbogen KA, Prystowsky EN, Halperin JL, Tamargo JL, Kay GN, Wann L, Jacobs AK, Anderson JL, Albert N, Hochman JS, Buller CE, Kushner FG, Creager MA, Ohman EM, Ettinger SM, Stevenson WG, Guyton RA, Tarkington LG, Halperin JL, Yancy CW; ACCF/AHA Task Force Members. 2011 ACCF/AHA/ HRS focused update on the management of patients with atrial fibril- lation (updating the 2006 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011;123:104 123. doi: 10.1161/ CIR.0b013e3181fa3cf4. 70. Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schuunemann HJ; American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis Panel. Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(suppl):7S 47S. 71. Bonow RO, Carabello BA, Chatterjee K, de Leon AC Jr, Faxon DP, Freed MD, Gaasch WH, Lytle BW, Nishimura RA, O Gara PT, O Rourke RA, Otto CM, Shah PM, Shanewise JS; 2006 Writing Committee Members; American College of Cardiology/American Heart Association Task Force. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart dis- ease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease). Circulation. 2008;118:e523 e661. doi: 10.1161/ CIRCULATIONAHA.108.190748. 72. Kulik A, Saltzman MB, Morris JJ. Dabigatran after cardiac surgery: cau- tion advised. J Thorac Cardiovasc Surg. 2011;142:1288. doi: 10.1016/j. jtcvs.2011.05.029. 73. Price J, Hynes M, Labinaz M, Ruel M, Boodhwani M. Mechanical valve thrombosis with dabigatran. J Am Coll Cardiol. 2012;60:1710 1711. doi: 10.1016/j.jacc.2012.06.039. 74. Eikelboom JW, Connolly SJ, Brueckmann M, Granger CB, Kappetein AP, Mack MJ, Blatchford J, Devenny K, Friedman J, Guiver K, Harper R, Khder Y, Lobmeyer MT, Maas H, Voigt JU, Simoons ML, Van de Werf F; RE-ALIGN Investigators. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013;369:1206 1214. doi: 10.1056/NEJMoa1300615. 75. Daida H, Yokoi H, Miyano H, Mokuno H, Satoh H, Kottke TE, Hosoda Y, Yamaguchi H. Relation of saphenous vein graft obstruction to serum cholesterol levels. J Am Coll Cardiol. 1995;25:193 197. 76. Campeau L, Enjalbert M, Lesp rance J, Bourassa MG, Kwiterovich P Jr, Wacholder S, Sniderman A. The relation of risk factors to the development of atherosclerosis in saphenous-vein bypass grafts and the progression of disease in the native circulation: a study 10 years after aortocoronary bypass surgery. N Engl J Med. 1984;311:1329 1332. doi: 10.1056/ NEJM198411223112101. 77. Cholesterol Treatment Trialists (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 par- ticipants in 26 randomised trials. Lancet. 2010;376:1670 1681. 78. Kulik A, Brookhart MA, Levin R, Ruel M, Solomon DH, Choudhry NK. Impact of statin use on outcomes after coronary artery bypass graft surgery. Circulation. 2008;118:1785 1792. doi: 10.1161/ CIRCULATIONAHA.108.799445. 79. Thielmann M, Neuh user M, Marr A, Jaeger BR, Wendt D, Schuetze B, Kamler M, Massoudy P, Erbel R, Jakob H. Lipid-lowering effect of preoperative statin therapy on postoperative major adverse cardiac events after coronary artery bypass surgery. J Thorac Cardiovasc Surg. 2007;134:1143 1149. doi: 10.1016/j.jtcvs.2007.07.029. 80. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R; Cholesterol Treatment Trialists (CTT) Collaborators. Efficacy and safety of cholesterol-lower- ing treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267 1278. doi: 10.1016/S0140-6736(05)67394-1. 81. Rossouw JE. Lipid-lowering interventions in angiographic trials. Am J Cardiol. 1995;76:86C 92C. 82. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, GoldbergAC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PWF. 2013 ACC/ AHA guideline on the treatment of blood cholesterol to reduce athero- sclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(suppl 2):S1 S45. doi: 10.1161/01. cir.0000437738.63853.7a. 83. Kulik A, Voisine P, Mathieu P, Masters RG, Mesana TG, Le May MR, Ruel M. Statin therapy and saphenous vein graft disease after coronary bypass surgery: analysis from the CASCADE randomized trial. Ann Thorac Surg. 2011;92:12841290. doi: 10.1016/j.athoracsur.2011.04.107. 84. Yang Z, Kozai T, van der Loo B, Viswambharan H, Lachat M, Turina MI, Malinski T, L scher TF. HMG-CoA reductase inhibition improves endothelial cell function and inhibits smooth muscle cell proliferation in human saphenous veins. J Am Coll Cardiol. 2000;36:1691 1697. 85. Indolfi C, Cioppa A, Stabile E, Di Lorenzo E, Esposito G, Pisani A, Leccia A, Cavuto L, Stingone AM, Chieffo A, Capozzolo C, Chiariello M. Effects of hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin on smooth muscle cell proliferation in vitro and neointimal formation in vivo after vascular injury. J Am Coll Cardiol. 2000;35:214 221. 86. Porter KE, Naik J, Turner NA, Dickinson T, Thompson MM, London NJ. Simvastatin inhibits human saphenous vein neointima formation via inhibition of smooth muscle cell proliferation and migration. J Vasc Surg. 2002;36:150 157. 87. Knatterud GL, Rosenberg Y, Campeau L, Geller NL, Hunninghake DB, Forman SA, Forrester JS, Gobel FL, Herd JA, Hickey A, Hoogwerf BJ, Terrin ML, White C. Long-term effects on clinical outcomes of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anti- coagulation in the Post Coronary Artery Bypass Graft Trial: Post CABG Investigators. Circulation. 2000;102:157 165. 88. Christenson JT. Preoperative lipid-control with simvastatin reduces the risk of postoperative thrombocytosis and thrombotic complications fol- lowing CABG. Eur J Cardiothorac Surg. 1999;15:394 399. 89. Christenson JT. Preoperative lipid control with simvastatin protects coro- nary artery bypass grafts from obstructive graft disease. Am J Cardiol. 2001;88:896 899, A8. 90. Aihara K, Miyauchi K, Kasai T, Kubota N, Kajimoto K, Tamura H, Kojima T,Yokoyama K, Kurata T, Amano A, Daida H. Long-term efficacy of pravastatin therapy in diabetic patients undergoing complete coronary revascularization. J Atheroscler Thromb. 2010;17:350 355. 91. Gan HL, Zhang JQ, Bo P, Wang SX, Lu CS. Statins decrease adverse out- comes in coronary artery bypass for extensive coronary artery disease as well as left main coronary stenosis. Cardiovasc Ther. 2010;28:70 79. doi: 10.1111/j.1755-5922.2009.00098.x. 92. Carrier M, Cossette M, Pellerin M, H bert Y, Bouchard D, Cartier R, Demers P, Jeanmart H, Pag P, Perrault LP. Statin treatment equalizes long-term survival between patients with single and bilateral internal tho- racic artery grafts. Ann Thorac Surg. 2009;88:789 795. doi: 10.1016/j. athoracsur.2009.04.097. 93. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation. 2004;109(suppl 1):III39 III43. doi: 10.1161/01. CIR.0000131517.20177.5a. 94. Lazar HL. Role of statin therapy in the coronary bypass patient. Ann Thorac Surg. 2004;78:730 740. doi: 10.1016/j.athoracsur.2003.12.041. 95. McFarlane SI, Muniyappa R, Francisco R, Sowers JR. Clinical review 145: pleiotropic effects of statins: lipid reduction and beyond. J Clin Endocrinol Metab. 2002;87:1451 1458. doi: 10.1210/jcem.87.4.8412. 96. Werba JP, Tremoli E, Massironi P, Camera M, Cannata A, Alamanni F, Biglioli P, Parolari A. Statins in coronary bypass surgery: rationale and clinical use. Ann Thorac Surg. 2003;76:2132 2140. 97. Cimino M, Gelosa P, Gianella A, Nobili E, Tremoli E, Sironi L. Statins: multiple mechanisms of action in the ischemic brain. Neuroscientist. 2007;13:208 213. doi: 10.1177/1073858406297121. 98. Merla R, Daher IN, Ye Y, Uretsky BF, Birnbaum Y. Pretreatment with statins may reduce cardiovascular morbidity and mortality after elective surgery and percutaneous coronary intervention: clinical evidence and possible underlying mechanisms. Am Heart J. 2007;154:391 402. doi: 10.1016/j.ahj.2007.04.029. 99. Chello M, Patti G, Candura D, Mastrobuoni S, Di Sciascio G, Agr F, Carassiti M, Covino E. Effects of atorvastatin on systemic inflammatory response after coronary bypass surgery. Crit Care Med. 2006;34:660 667. doi: 10.1097/01.CCM.0000201407.89977.EA. 100. Chello M, Anselmi A, Spadaccio C, Patti G, Goffredo C, Di Sciascio G, Covino E. Simvastatin increases neutrophil apoptosis and reduces inflammatory reaction after coronary surgery. Ann Thorac Surg. 2007;83:1374 1380. doi: 10.1016/j.athoracsur.2006.10.065. 101. Nakamura K, Masuda H, Kariyazono H, Arima J, Iguro Y, Yamada K, Sakata R. Effects of atorvastatin and aspirin combined therapy on inflammatory responses in patients undergoing coronary artery bypass grafting. Cytokine. 2006;36:201 210. doi: 10.1016/j.cyto.2006.11.001. 102. Dereli Y, Ege E, Kurban S, Narin C, Sarig l A, Yeniterzi M. Pre- operative atorvastatin therapy to decrease the systemic inflamma- tory response after coronary artery bypass grafting. J Int Med Res. 2008;36:1248 1254. 103. Pound EM, Kang JX, LeafA. Partitioning of polyunsaturated fatty acids, which prevent cardiac arrhythmias, into phospholipid cell membranes. J Lipid Res. 2001;42:346 351. 104. Patti G, Chello M, Candura D, Pasceri V, D Ambrosio A, Covino E, Di Sciascio G. Randomized trial of atorvastatin for reduction of post- operative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study. Circulation. 2006;114:1455 1461. doi: 10.1161/CIRCULATIONAHA.106.621763. 105. Kourliouros A, De Souza A, Roberts N, Marciniak A, Tsiouris A, Valencia O, Camm J, Jahangiri M. Dose-related effect of statins on atrial fibrillation after cardiac surgery. Ann Thorac Surg. 2008;85:1515 1520. doi: 10.1016/j.athoracsur.2008.01.040. 106. SongYB, OnYK, Kim JH, Shin DH, Kim JS, Sung J, Lee SH, Kim WS, Lee YT. The effects of atorvastatin on the occurrence of postoperative atrial fibrillation after off-pump coronary artery bypass grafting surgery. Am Heart J. 2008;156:373.e9 373.16. doi: 10.1016/j.ahj.2008.04.020. 107. Lertsburapa K, White CM, Kluger J, Faheem O, Hammond J, Coleman CI. Preoperative statins for the prevention of atrial fibrillation after car- diothoracic surgery. J Thorac Cardiovasc Surg. 2008;135:405 411. doi: 10.1016/j.jtcvs.2007.08.049. 108. Mithani S, Akbar MS, Johnson DJ, Kuskowski M, Apple KK, Bonawitz- Conlin J, Ward HB, Kelly RF, McFalls EO, Bloomfield HE, Li JM, Adabag S. Dose dependent effect of statins on postoperative atrial fibril- lation after cardiac surgery among patients treated with beta blockers. J Cardiothorac Surg. 2009;4:61. doi: 10.1186/1749-8090-4-61. 109. KulikA, Singh JP, Levin R,Avorn J, Choudhry NK.Association between statin use and the incidence of atrial fibrillation following hospitalization for coronary artery disease. Am J Cardiol. 2010;105:1655 1660. doi: 10.1016/j.amjcard.2010.01.341. 110. Liakopoulos OJ, ChoiYH, Kuhn EW,WittwerT, Borys M, Madershahian N, Wassmer G, Wahlers T. Statins for prevention of atrial fibrillation after cardiac surgery: a systematic literature review. J Thorac Cardiovasc Surg. 2009;138:678 686.e1. doi: 10.1016/j.jtcvs.2009.03.054. 111. Huffmyer JL, Mauermann WJ, Thiele RH, Ma JZ, Nemergut EC. Preoperative statin administration is associated with lower mortality and decreased need for postoperative hemodialysis in patients undergo- ing coronary artery bypass graft surgery. J Cardiothorac Vasc Anesth. 2009;23:468 473. doi: 10.1053/j.jvca.2008.11.005. 112. Tabata M, Khalpey Z, Pirundini PA, Byrne ML, Cohn LH, Rawn JD. Renoprotective effect of preoperative statins in coronary artery bypass grafting. Am J Cardiol. 2007;100:442 444. doi: 10.1016/j. amjcard.2007.03.071. 113. Coleman CI, Lucek DM, Hammond J, White CM. Preoperative statins and infectious complications following cardiac surgery. Curr Med Res Opin. 2007;23:1783 1790. doi: 10.1185/030079907X210570. 114. Aboyans V, Labrousse L, Lacroix P, Guilloux J, Sekkal S, Le Guyader A, Cornu E, Laskar M. Predictive factors of stroke in patients undergo- ing coronary bypass grafting: statins are protective. Eur J Cardiothorac Surg. 2006;30:300 304. doi: 10.1016/j.ejcts.2006.03.066. 115. Bouchard D, Carrier M, Demers P, Cartier R, Pellerin M, Perrault LP, Lambert J. Statin in combination with -blocker therapy reduces post- operative stroke after coronary artery bypass graft surgery. Ann Thorac Surg. 2011;91:654 659. doi: 10.1016/j.athoracsur.2010.11.036. 116. Liakopoulos OJ, Choi YH, Haldenwang PL, Strauch J, Wittwer T, Dorge H, Stamm C, Wassmer G, Wahlers T. Impact of preoperative statin therapy on adverse postoperative outcomes in patients undergoing cardiac surgery: a meta-analysis of over 30,000 patients. Eur Heart J. 2008;29:1548 1559. 117. Pan W, Pintar T, Anton J, Lee VV, Vaughn WK, Collard CD. Statins are associated with a reduced incidence of perioperative mortality after coronary artery bypass graft surgery. Circulation. 2004;110(suppl 1):II45 II49. doi: 10.1161/01.CIR.0000138316.24048.08. 118. Takagi H, Umemoto T. A meta-analysis of controlled studies of preop- erative statin therapy for prevention of postoperative mortality in cardiac surgery. J Thorac Cardiovasc Surg. 2009;138:790 791; author reply 792. 119. Vaduganathan M, Stone NJ, Lee R, McGee EC Jr, Malaisrie SC, Silverberg RA, Kansal P, McCarthy PM. Perioperative statin therapy reduces mortality in normolipidemic patients undergoing cardiac sur- gery. J Thorac Cardiovasc Surg. 2010;140:1018 1027. doi: 10.1016/j. jtcvs.2010.08.002. 120. Dotani MI, Elnicki DM, Jain AC, Gibson CM. Effect of preoperative statin therapy and cardiac outcomes after coronary artery bypass graft- ing. Am J Cardiol. 2000;86:1128 1130, A6. 121. Clark LL, Ikonomidis JS, Crawford FA Jr, Crumbley A 3rd, Kratz JM, Stroud MR, Woolson RF, Bruce JJ, Nicholas JS, Lackland DT, Zile MR, Spinale FG. Preoperative statin treatment is associated with reduced postoperative mortality and morbidity in patients undergoing cardiac surgery: an 8-year retrospective cohort study. J Thorac Cardiovasc Surg. 2006;131:679 685. doi: 10.1016/j.jtcvs.2005.11.006. 122. Collard CD, Body SC, Shernan SK, Wang S, Mangano DT; Multicenter Study of Perioperative Ischemia (MCSPI) Research Group, Inc; Ischemia Research and Education Foundation (IREF) Investigators. Preoperative statin therapy is associated with reduced cardiac mortality after coronary artery bypass graft surgery. J Thorac Cardiovasc Surg. 2006;132:392 400. doi: 10.1016/j.jtcvs.2006.04.009. 123. Kulik A, Levin R, Ruel M, Mesana TG, Solomon DH, Choudhry NK. Patterns and predictors of statin use after coronary artery bypass graft surgery. J Thorac Cardiovasc Surg. 2007;134:932 938. doi: 10.1016/j. jtcvs.2007.05.039. 124. Cannon CP, Steinberg BA, Murphy SA, Mega JL, Braunwald E. Meta- analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol. 2006;48:438 445. doi: 10.1016/j.jacc.2006.04.070. 125. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK; Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425 1435. doi: 10.1056/NEJMoa050461. 126. Shah SJ, Waters DD, Barter P, Kastelein JJ, Shepherd J, Wenger NK, DeMicco DA, Breazna A, LaRosa JC. Intensive lipid-lowering with atorvastatin for secondary prevention in patients after coronary artery bypass surgery. J Am Coll Cardiol. 2008;51:1938 1943. doi: 10.1016/j. jacc.2007.12.054. 127. Brilakis ES, de Lemos JA, Cannon CP, Wiviott SD, Murphy SA, Morrow DA, Sabatine MS, Banerjee S, Blazing MA, Califf RM, Braunwald E. Outcomes of patients with acute coronary syndrome and previous coronary artery bypass grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the Aggrastat to Zocor [A to Z] trials). Am J Cardiol. 2008;102:552 558. doi: 10.1016/j.amjcard.2008.04.024. 128. Ouattara A, Benhaoua H, Le Manach Y, Mabrouk-Zerguini N, Itani O, Osman A, Landi M, Riou B, Coriat P. Perioperative statin therapy is Kulik et al Secondary Prevention After CABG 955 associated with a significant and dose-dependent reduction of adverse cardiovascular outcomes after coronary artery bypass graft sur- gery. J Cardiothorac Vasc Anesth. 2009;23:633 638. doi: 10.1053/j. jvca.2009.02.008. 129. Hata M, Takayama T, Sezai A, Yoshitake I, Hirayama A, Minami K. Efficacy of aggressive lipid controlling therapy for preventing saphe- nous vein graft disease. Ann Thorac Surg. 2009;88:1440 1444. doi: 10.1016/j.athoracsur.2009.06.009. 130. Black DM. A general assessment of the safety of HMG CoA reductase inhibitors (statins). Curr Atheroscler Rep. 2002;4:34 41. 131. Armitage J. The safety of statins in clinical practice. Lancet. 2007;370:1781 1790. doi: 10.1016/S0140-6736(07)60716-8. 132. Pasternak RC, Smith SC Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C; American College of Cardiology; American Heart Association; National Heart, Lung and Blood Institute. ACC/AHA/ NHLBI clinical advisory on the use and safety of statins. Circulation. 2002;106:1024 1028. 133. Hindler K, Shaw AD, Samuels J, Fulton S, Collard CD, Riedel B. Improved postoperative outcomes associated with preoperative statin therapy. Anesthesiology. 2006;105:1260 1272; quiz 1289. 134. Kulik A, Ruel M. Statins and coronary artery bypass graft surgery: pre- operative and postoperative efficacy and safety. Expert Opin Drug Saf. 2009;8:559 571. doi: 10.1517/14740330903188413. 135. Vecchione C, Brandes RP. Withdrawal of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors elicits oxidative stress and induces endothelial dysfunction in mice. Circ Res. 2002;91:173 179. 136. Billings FT 4th, Pretorius M, Siew ED, Yu C, Brown NJ. Early post- operative statin therapy is associated with a lower incidence of acute kidney injury after cardiac surgery. J Cardiothorac Vasc Anesth. 2010;24:913 920. 137. Le Manach Y, Godet G, Coriat P, Martinon C, Bertrand M, Fl ron MH, Riou B. The impact of postoperative discontinuation or continu- ation of chronic statin therapy on cardiac outcome after major vas- cular surgery. Anesth Analg. 2007;104:1326 1333. doi: 10.1213/01. ane.0000263029.72643.10. 138. Serruys PW, Morice MC, Kappetein AP, Colombo A, Holmes DR, Mack MJ, St hle E, Feldman TE, van den Brand M, Bass EJ, Van Dyck N, Leadley K, Dawkins KD, Mohr FW; SYNTAX Investigators. Percutaneous coronary intervention versus coronary-artery bypass graft- ing for severe coronary artery disease. N Engl J Med. 2009;360:961 972. doi: 10.1056/NEJMoa0804626. 139. Kulik A, Shrank WH, Levin R, Choudhry NK. Adherence to statin therapy in elderly patients after hospitalization for coronary revas- cularization. Am J Cardiol. 2011;107:1409 1414. doi: 10.1016/j. amjcard.2011.01.013. 140. Sedjo RL, Cox ER. Lowering copayments: impact of simvastatin patent expiration on patient adherence. Am J Manag Care. 2008;14:813 818. 141. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ; National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227 239. doi: 10.1161/01. CIR.0000133317.49796.0E. 142. Barter P. HDL-C: role as a risk modifier. Atheroscler Suppl. 2011;12:267 270. doi: 10.1016/S1567-5688(11)70885-6. 143. AIM-HIGH Investigators, Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, McBride R, Teo K, Weintraub W. Niacin in patients with low HDL cholesterol levels receiv- ing intensive statin therapy. N Engl J Med. 2011;365:2255 2267. 144. Taylor AJ, Villines TC, Stanek EJ, Devine PJ, Griffen L, Miller M, Weissman NJ, Turco M. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med. 2009;361:2113 2122. doi: 10.1056/NEJMoa0907569. 145. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B; ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coro- nary events. N Engl J Med. 2007;357:2109 2122. doi: 10.1056/ NEJMoa0706628. 146. Birjmohun RS, Hutten BA, Kastelein JJ, Stroes ES. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. J Am Coll Cardiol. 2005;45:185 197. doi: 10.1016/j.jacc.2004.10.031. 147. Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS, Dowdy AA, Marino EK, Bolson EL, Alaupovic P, Frohlich J, Albers JJ. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001;345:1583 1592. doi: 10.1056/NEJMoa011090. 148. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. Predicting coronary heart disease in middle-aged and older persons: the Framington study. JAMA. 1977;238:497 499. 149. Castelli WP, Doyle JT, Gordon T, Hames CG, Hjortland MC, Hulley SB, Kagan A, Zukel WJ. HDL cholesterol and other lipids in coronary heart disease: the Cooperative Lipoprotein Phenotyping Study. Circulation. 1977;55:767 772. 150. Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol lev- els: the Framingham Study. JAMA. 1986;256:2835 2838. 151. Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, Kastelein JJ, Bittner V, Fruchart JC; Treating to New Targets Investigators. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med. 2007;357:1301 1310. doi: 10.1056/NEJMoa064278. 152. Seo SM, Choo EH, KohYS, Park MW, Shin DI, ChoiYS, Park HJ, Kim DB, Her SH, Lee JM, Park CS, Kim PJ, Moon KW, Chang K, Kim HY, Yoo KD, Jeon DS, Chung WS, ParkYG, Seung KB; Catholic University of Korea, Percutaneous Coronary Intervention Registry Investigators. High-density lipoprotein cholesterol as a predictor of clinical outcomes in patients achieving low-density lipoprotein cholesterol targets with statins after percutaneous coronary intervention. Heart. 2011;97:1943 1950. doi: 10.1136/hrt.2011.225466. 153. Nicholls SJ, Tuzcu EM, Sipahi I, Grasso AW, Schoenhagen P, Hu T, Wolski K, Crowe T, Desai MY, Hazen SL, Kapadia SR, Nissen SE. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA. 2007;297:499 508. doi: 10.1001/ jama.297.5.499. 154. Taylor AJ, Lee HJ, Sullenberger LE. The effect of 24 months of com- bination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3. Curr Med Res Opin. 2006;22:2243 2250. doi: 10.1185/030079906X148508. cebo-controlled trial in 25 673 high-risk patients of ER niacin/laropip- rant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J. 2013;34:1279 1291. 156. Frick MH, Syv nne M, Nieminen MS, Kauma H, Majahalme S, Virtanen V, Kes niemi YA, Pasternack A, Taskinen MR. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol: Lopid Coronary Angiography Trial (LOCAT) Study Group. Circulation. 1997;96:2137 2143. 157. Ericsson CG, Hamsten A, Nilsson J, Grip L, Svane B, de Faire U. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet. 1996;347:849 853. 158. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet. 2001;357:905 910. 159. ACCORD Study Group. Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd, Leiter LA, Linz P, FriedewaldWT, Buse JB, Gerstein HC, Probstfield J, Grimm RH, Ismail-Beigi F, Bigger JT, Goff DC Jr, Cushman WC, Simons-Morton DG, Byington RP. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:1563 1574. 160. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kes niemi YA, Sullivan D, Hunt D, Colman P, d Emden M, Whiting M, Ehnholm C, Laakso M; FIELD Study Investigators. Effects of long-term fenofibrate therapy on cardio- vascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366:1849 1861. doi: 10.1016/S0140-6736(05)67667-2. 161. Khera AV, Patel PJ, Reilly MP, Rader DJ. The addition of niacin to statin therapy improves high-density lipoprotein cholesterol levels but not metrics of functionality. J Am Coll Cardiol. 2013;62:1909 1910. doi: 10.1016/j.jacc.2013.07.025. 162. Rod s-Cabau J, Facta A, Larose E, DeLarochelli re R, D ry JP, Nguyen CM, Roy L, Proulx G, Gleeton O, Barbeau G, No l B, Rouleau J, Boudreault JR, Bertrand OF. Predictors of aorto-saphenous vein bypass narrowing late after coronary artery bypass grafting. Am J Cardiol. 2007;100:640 645. doi: 10.1016/j.amjcard.2007.03.080. 163. Foody JM, Ferdinand FD, Pearce GL, Lytle BW, Cosgrove DM, Sprecher DL. HDL cholesterol level predicts survival in men after coro- nary artery bypass graft surgery: 20-year experience from The Cleveland Clinic Foundation. Circulation. 2000;102(suppl 3):III90 III94. 164. Sabik JF 3rd, Blackstone EH, Gillinov AM, Smedira NG, Lytle BW. Occurrence and risk factors for reintervention after coronary artery bypass grafting. Circulation. 2006;114(suppl):I454 I460. doi: 10.1161/ CIRCULATIONAHA.105.001149. 165. Domanski MJ, Borkowf CB, Campeau L, Knatterud GL, White C, Hoogwerf B, Rosenberg Y, Geller NL. Prognostic factors for athero- sclerosis progression in saphenous vein grafts: the Postcoronary Artery Bypass Graft (Post-CABG) trial: Post-CABG Trial Investigators. J Am Coll Cardiol. 2000;36:1877 1883. 166. Jerzewski K, Ruel M, Voisine P, Le May MR, Kulik A. Does high- density lipoprotein influence the development of saphenous vein graft disease after coronary bypass surgery?: exploratory analysis from the CASCADE trial. J Cardiothorac Surg. 2013;8:172. doi: 10.1186/1749-8090-8-172. 167. Jones PH, Davidson MH. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol. 2005;95:120 122. doi: 10.1016/j.amjcard.2004.08.076. 168. Bottorff MB. Statin safety and drug interactions: clinical implications. Am J Cardiol. 2006;97:27C 31C. doi: 10.1016/j.amjcard.2005.12.007. 169. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein choles- terol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk. 1996;3:213 219. 170. Assmann G, Schulte H, Cullen P, Seedorf U. Assessing risk of myocar- dial infarction and stroke: new data from the Prospective Cardiovascular M nster (PROCAM) study. Eur J Clin Invest. 2007;37:925 932. doi: 10.1111/j.1365-2362.2007.01888.x. 171. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143 3421. 172. Cui Y, Blumenthal RS, Flaws JA, Whiteman MK, Langenberg P, Bachorik PS, Bush TL. Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch Intern Med. 2001;161:1413 1419. 173. Robinson JG, Wang S, Smith BJ, Jacobson TA. Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk. J Am Coll Cardiol. 2009;53:316 322. doi: 10.1016/j.jacc.2008.10.024. 174. Rubins HB, Robins SJ, Collins D, Fye CL,Anderson JW, Elam MB, Faas FH, Linares E, Schaefer EJ, Schectman G, Wilt TJ, Wittes J. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol: Veterans Affairs High- Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999;341:410 418. doi: 10.1056/NEJM199908053410604. 175. McKeageK,KeatingGM.Fenofibrate:areviewofitsuseindyslipidaemia. Drugs. 2011;71:1917 1946. doi: 10.2165/11208090-000000000-00000. 176. Genuth S, Ismail-Beigi F. Clinical implications of the ACCORD trial. J Clin Endocrinol Metab. 2012;97:41 48. doi: 10.1210/jc.2011-1679. 177. Sprecher DL, Pearce GL, Cosgrove DM, Lytle BW, Loop FD, Pashkow FJ. Relation of serum triglyceride levels to survival after coronary artery bypass grafting. Am J Cardiol. 2000;86:285 288. 178. Allard C, Ruscito O, Goulet C. The influence of serum triglycerides on the fate of aorto-coronary vein grafts. Can Med Assoc J. 1972;107:213 216. 179. Yli-M yry S, Huikuri HV. Clinical and angiographic prediction of myocardial infarction and recurrence of severe angina during a five- year follow-up after coronary artery bypass grafting. Am J Cardiol. 1993;72:1371 1375. 180. Voors AA, van Brussel BL, Kelder JC, Plokker HW. Usefulness of hypertriglyceridemia in predicting myocardial infarction late after coro- nary artery bypass operation. Am J Cardiol. 1997;79:1350 1354. 181. Lind n T, Bondjers G, Karlsson T, Wiklund O. Serum triglycerides and HDL cholesterol: major predictors of long-term survival after coronary surgery. Eur Heart J. 1994;15:747 752. 182. Mennander A, Angervuori T, Huhtala H, Karhunen P, Tarkka M, Kuukasj rvi P. Positive family history of coronary atherosclero- sis and serum triglycerides may predict repeated coronary artery bypass surgery. Scand Cardiovasc J. 2005;39:225 228. doi: 10.1080/14017430510035925. 183. Fox MH, Gruchow HW, Barboriak JJ, Anderson AJ, Hoffmann RG, Flemma RJ, King JF. Risk factors among patients undergoing repeat aorta-coronary bypass procedures. J Thorac Cardiovasc Surg. 1987;93:56 61. 184. Rapp JH, LespineA, Hamilton RL, Colyvas N, ChaumetonAH,Tweedie- Hardman J, Kotite L, Kunitake ST, Havel RJ, Kane JP. Triglyceride-rich lipoproteins isolated by selected-affinity anti-apolipoprotein B immu- nosorption from human atherosclerotic plaque. Arterioscler Thromb. 1994;14:1767 1774. 185. Kalan JM, Roberts WC. Morphologic findings in saphenous veins used as coronary arterial bypass conduits for longer than 1 year: necropsy analysis of 53 patients, 123 saphenous veins, and 1865 five-millimeter segments of veins. Am Heart J. 1990;119:1164 1184. 186. Barbir M, Hunt BJ, Galloway D, Taylor A, Ilsley C, Mitchell A, Yacoub M. A randomized pilot trial of low-dose combination lipid-lowering therapy following coronary artery bypass grafting. Clin Cardiol. 1994;17:59 64. 187. Shin J, Johnson JA. Pharmacogenetics of beta-blockers. Pharmacotherapy. 2007;27:874 887. doi: 10.1592/phco.27.6.874. 188. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis. 1985;27:335 371. 189. Chen J, Radford MJ, Wang Y, Marciniak TA, Krumholz HM. Are beta-blockers effective in elderly patients who undergo coronary revascularization after acute myocardial infarction? Arch Intern Med. 2000;160:947 952. 190. Ferguson TB Jr, Coombs LP, Peterson ED; Society of Thoracic Surgeons National Adult Cardiac Surgery Database. Preoperative beta-blocker use and mortality and morbidity following CABG surgery in NorthAmerica. JAMA. 2002;287:2221 2227. 191. Foody JM, Ferdinand FD, Galusha D, Rathore SS, Masoudi FA, Havranek EP, Nilasena D, Radford MJ, Krumholz HM. Patterns of secondary prevention in older patients undergoing coronary artery bypass grafting during hospitalization for acute myocardial infarction. Circulation. 2003;108(suppl 1):II24 II28. 192. Holman WL, Sansom M, Kiefe CI, Peterson ED, Hubbard SG, Delong JF, Allman RM. Alabama Coronary Artery Bypass Grafting Project: results from phase II of a statewide quality improvement initiative. Ann Surg. 2004;239:99 109. doi: 10.1097/01.sla.0000103065.17661.8f. 193. Williams JB, Delong ER, Peterson ED, Dokholyan RS, Ou FS, Ferguson TB Jr; Society of Thoracic Surgeons and the National Cardiac Database. Secondary prevention after coronary artery bypass graft surgery: find- ings of a national randomized controlled trial and sustained society-led incorporation into practice. Circulation. 2011;123:39 45. doi: 10.1161/ CIRCULATIONAHA.110.981068. 194. Yam FK, Akers WS, Ferraris VA, Smith K, Ramaiah C, Camp P, Flynn JD. Interventions to improve guideline compliance following coronary artery bypass grafting. Surgery. 2006;140:541 547. doi: 10.1016/j. surg.2006.05.014. 195. Hiratzka LF, Eagle KA, Liang L, Fonarow GC, LaBresh KA, Peterson ED; Get With the Guidelines Steering Committee. Atherosclerosis secondary prevention performance measures after coronary bypass graft surgery compared with percutaneous catheter interven- tion and nonintervention patients in the Get With the Guidelines database. Circulation. 2007;116(suppl):I207 I212. doi: 10.1161/ CIRCULATIONAHA.106.681247. 196. Sj land H, Caidahl K, Lurje L, Hjalmarson A, Herlitz J. Metoprolol treatment for two years after coronary bypass grafting: effects on exercise capacity and signs of myocardial ischaemia. Br Heart J. 1995;74:235 241. 197. Effect of metoprolol on death and cardiac events during a 2-year period after coronary artery bypass grafting: the MACB Study Group. Eur Heart J. 1995;16:1825 1832. 198. Goyal A, Alexander JH, Hafley GE, Graham SH, Mehta RH, Mack MJ, Wolf RK, Cohn LH, Kouchoukos NT, Harrington RA, Gennevois D, Gibson CM, Califf RM, Ferguson TB Jr, Peterson ED; PREVENT IV Investigators. Outcomes associated with the use of secondary preven- tion medications after coronary artery bypass graft surgery. Ann Thorac Surg. 2007;83:993 1001. doi: 10.1016/j.athoracsur.2006.10.046. 199. Bangalore S, Steg G, Deedwania P, Crowley K, Eagle KA, Goto S, Ohman EM, Cannon CP, Smith SC, Zeymer U, Hoffman EB, Messerli FH, Bhatt DL; REACH Registry Investigators. -Blocker use and clini- cal outcomes in stable outpatients with and without coronary artery dis- ease. JAMA. 2012;308:1340 1349. doi: 10.1001/jama.2012.12559. Kulik et al Secondary Prevention After CABG 957 200. Ad N, Barnett SD, Haan CK, O Brien SM, Milford-Beland S, Speir AM. Does preoperative atrial fibrillation increase the risk for mortality and morbidity after coronary artery bypass grafting? J Thorac Cardiovasc Surg. 2009;137:901 906. doi: 10.1016/j.jtcvs.2008.09.050. 201. Crystal E, Garfinkle MS, Connolly SS, Ginger TT, Sleik K, Yusuf SS. Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery. Cochrane Database Syst Rev. 2004:CD003611. 202. Khan MF, Wendel CS, Movahed MR. Prevention of post-coronary artery bypass grafting (CABG) atrial fibrillation: efficacy of prophylactic beta-blockers in the modern era: a meta-analysis of latest randomized controlled trials. Ann Noninvasive Electrocardiol. 2013;18:58 68. doi: 10.1111/anec.12004. 203. O Brien SM, Shahian DM, DeLong ER, Normand SL, Edwards FH, Ferraris VA, Haan CK, Rich JB, Shewan CM, Dokholyan RS, Anderson RP, Peterson ED. Quality measurement in adult cardiac surgery, part 2: statistical considerations in composite measure scoring and provider rating. Ann Thorac Surg. 2007;83(suppl):S13 S26. doi: 10.1016/j. athoracsur.2007.01.055. 204. Brinkman WT, Herbert MA, Prince SL, Magee MJ, Dewey TM, Smith RL, Edgerton JR, Head SJ, Ryan WH, Mack MJ. Preoperative beta- blocker usage: is it really worthy of being a quality indicator? Ann Thorac Surg. 2011;92:788 795. doi: 10.1016/j.athoracsur.2011.03.088. 205. Bangalore S, Messerli FH, Kostis JB, Pepine CJ. Cardiovascular protec- tion using beta-blockers: a critical review of the evidence. J Am Coll Cardiol. 2007;50:563 572. doi: 10.1016/j.jacc.2007.04.060. 206. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortal- ity among high-risk and low-risk patients after myocardial infarction. N Engl J Med. 1998;339:489 497. doi: 10.1056/NEJM199808203390801. 207. Freemantle N, Cleland J, Young P, Mason J, Harrison J. Beta block- ade after myocardial infarction: systematic review and meta regression analysis. BMJ. 1999;318:1730 1737. 208. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353:9 13. J, Wikstrand J, El Allaf D, V tovec J, Aldershvile J, Halinen M, Dietz R, Neuhaus KL, J nosi A, Thorgeirsson G, Dunselman PH, Gullestad L, Kuch J, Herlitz J, Rickenbacher P, Ball S, Gottlieb S, Deedwania P. Effects of controlled-release metoprolol on total mortality, hospital- izations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF): MERIT-HF Study Group. JAMA. 2000;283:1295 1302. 210. Packer M, CoatsAJ, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Roecker EB, Schultz MK, DeMets DL; Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344:1651 1658. doi: 10.1056/NEJM200105313442201. 211. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN ran- domised trial. Lancet. 2001;357:1385 1390. 212. Mehta RH, Bhatt DL, Steg PG, Goto S, Hirsch AT, Liau CS, R ther J, Wilson PW, Richard AJ, Eagle KA, Ohman EM; REACH Registry Investigators. Modifiable risk factors control and its relationship with 1 year outcomes after coronary artery bypass surgery: insights from the REACH registry. Eur Heart J. 2008;29:3052 3060. doi: 10.1093/ eurheartj/ehn478. 213. Chan AY, McAlister FA, Norris CM, Johnstone D, Bakal JA, Ross DB; Alberta Provincial Program for Outcome Assessment in Coronary Heart Disease (APPROACH) Investigators. Effect of beta-blocker use on outcomes after discharge in patients who underwent cardiac surgery. J Thorac Cardiovasc Surg. 2010;140:182 187, 187.e1. doi: 10.1016/j. jtcvs.2010.03.015. 214. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145 153. doi: 10.1056/ NEJM200001203420301. 215. Boatman DM, Saeed B, Varghese I, Peters CT, Daye J, Haider A, Roesle M, Banerjee S, Brilakis ES. Prior coronary artery bypass graft surgery patients undergoing diagnostic coronary angiography have mul- tiple uncontrolled coronary artery disease risk factors and high risk for cardiovascular events. Heart Vessels. 2009;24:241 246. doi: 10.1007/ s00380-008-1114-1. 216. Rosendorff C, Black HR, Cannon CP, Gersh BJ, Gore J, Izzo JL Jr, Kaplan NM, O Connor CM, O Gara PT, Oparil S. Treatment of hypertension in the prevention and management of ischemic heart disease: a scien- tific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation. 2007;115:2761 2788. doi: 10.1161/CIRCULATIONAHA.107.183885. 217. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, B hm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, ManolisAJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34:2159 2219. doi: 10.1093/eurheartj/eht151. 218. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, Lackland DT, LeFevre ML, MacKenzie TD, Ogedegbe O, Smith SC Jr, Svetkey LP, Taler SJ, Townsend RR, Wright JT Jr, Narva AS, Ortiz E. 2014 Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311:507 520. doi: 10.1001/jama.2013.284427. 219. Go AS, Bauman MA, Coleman King SM, Fonarow GC, Lawrence W, Williams KA, Sanchez E; American Heart Association; American College of Cardiology; Centers for Disease Control and Prevention. An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention. Hypertension. 2014;63:878 885. doi: 10.1161/HYP.0000000000000003. 220. ACCORD Study Group, Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA, Simons-Morton DG, Basile JN, Corson MA, Probstfield JL, Katz L, Peterson KA, Friedewald WT, Buse JB, Bigger JT, Gerstein HC, Ismail-Beigi F. Effects of inten- sive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362:1575 1585. 221. Fox KM; EURopean trial On reduction of cardiac events with Perindopril in stable coronaryArtery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicen- tre trial (the EUROPA study). Lancet. 2003;362:782 788. 222. Nissen SE, Tuzcu EM, Libby P, Thompson PD, Ghali M, Garza D, Berman L, Shi H, Buebendorf E, Topol EJ; CAMELOT Investigators. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA. 2004;292:2217 2225. doi: 10.1001/jama.292.18.2217. 223. Pitt B, Byington RP, Furberg CD, Hunninghake DB, Mancini GB, Miller ME, Riley W. Effect of amlodipine on the progression of athero- sclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation. 2000;102:1503 1510. 224. Poole-Wilson PA, Lubsen J, Kirwan BA, van Dalen FJ, Wagener G, Danchin N, Just H, Fox KA, Pocock SJ, Clayton TC, Motro M, Parker JD, Bourassa MG, Dart AM, Hildebrandt P, Hjalmarson A, Kragten JA, Molhoek GP, Otterstad JE, Seabra-Gomes R, Soler-Soler J, Weber S; Coronary disease Trial Investigating Outcome with Nifedipine gastro- intestinal therapeutic system Investigators. Effect of long-acting nife- dipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet. 2004;364:849 857. doi: 10.1016/S0140-6736(04)16980-8. 225. Braunwald E, Domanski MJ, Fowler SE, Geller NL, Gersh BJ, Hsia J, Pfeffer MA, Rice MM, Rosenberg YD, Rouleau JL; PEACE Trial Investigators. Angiotensin-converting-enzyme inhibition in stable coro- nary artery disease. N Engl J Med. 2004;351:2058 2068. doi: 10.1056/ NEJMoa042739. 226. Liu L, Zhang Y, Liu G, Li W, Zhang X, Zanchetti A; FEVER Study Group. The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients. J Hypertens. 2005;23:2157 2172. 227. Hansson L, Zanchetti A, Carruthers SG, Dahl f B, Elmfeldt D, Julius S, M nard J, Rahn KH, Wedel H, Westerling S. Effects of intensive blood- pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) ran- domised trial. HOT Study Group. Lancet. 1998;351:1755 1762. 228. Tight blood pressure control and risk of macrovascular and microvas- cular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ. 1998;317:703 713. 229. Agarwal R, Bills JE, Hecht TJ, Light RP. Role of home blood pressure monitoring in overcoming therapeutic inertia and improving hyperten- sion control: a systematic review and meta-analysis. Hypertension. 2011;57:29 38. doi: 10.1161/HYPERTENSIONAHA.110.160911. 230. Sica DA. Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats. Drugs. 2002;62:443 462. 231. Schoolwerth AC, Sica DA, Ballermann BJ, Wilcox CS. Renal con- siderations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association. Circulation. 2001;104:1985 1991. 232. Oosterga M, Voors AA, Pinto YM, Buikema H, Grandjean JG, Kingma JH, Crijns HJ, van Gilst WH. Effects of quinapril on clinical out- come after coronary artery bypass grafting (the QUO VADIS Study): QUinapril on VascularAce and Determinants of Ischemia. Am J Cardiol. 2001;87:542 546. 233. Rouleau JL, Warnica WJ, Baillot R, Block PJ, Chocron S, Johnstone D, Myers MG, Calciu CD, Dalle-Ave S, Martineau P, Mormont C, van Gilst WH; IMAGINE (Ischemia Management with Accupril post-bypass Graft via Inhibition of the coNverting Enzyme) Investigators. Effects of angiotensin-converting enzyme inhibition in low-risk patients early after coronary artery bypass surgery. Circulation. 2008;117:24 31. doi: 10.1161/CIRCULATIONAHA.106.685073. 234. Sica DA. Diuretic use in renal disease. Nat Rev Nephrol. 2011;8:100 109. doi: 10.1038/nrneph.2011.175. 235. Zannad F, Gattis Stough W, Rossignol P, Bauersachs J, McMurray JJ, Swedberg K, Struthers AD, Voors AA, Ruilope LM, Bakris GL, O Connor CM, Gheorghiade M, Mentz RJ, Cohen-Solal A, Maggioni AP, Beygui F, Filippatos GS, Massy ZA, Pathak A, Pi a IL, Sabbah HN, Sica DA, Tavazzi L, Pitt B. Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. Eur Heart J. 2012;33:2782 2795. doi: 10.1093/ eurheartj/ehs257. 236. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJV, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WHW, Tsai EJ, Wilkoff BL. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;128:e240 e327. doi: 10.1161/ CIR.0b013e31829e8776. 237. Jneid H, Moukarbel GV, Dawson B, Hajjar RJ, Francis GS. Combining neuroendocrine inhibitors in heart failure: reflections on safety and efficacy. Am J Med. 2007;120:1090.e1 1090.e8. doi: 10.1016/j. amjmed.2007.02.029. 238. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001 2007. 239. Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, Lubsen J, Lutiger B, Metra M, Remme WJ, Torp-Pedersen C, Scherhag A, Skene A; Carvedilol Or Metoprolol European Trial Investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. 2003;362:7 13. doi: 10.1016/S0140-6736(03)13800-7. 240. Cruden NL, Witherow FN, Webb DJ, Fox KA, Newby DE. Bradykinin contributes to the systemic hemodynamic effects of chronic angio- tensin-converting enzyme inhibition in patients with heart failure. Arterioscler Thromb Vasc Biol. 2004;24:1043 1048. doi: 10.1161/01. ATV.0000129331.21092.1d. 241. Pfeffer MA, Braunwald E, Moy LA, Basta L, Brown EJ Jr, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, Klein M, Lamas GA, Packer M, Rouleau J, Rouleau JL, Rutherford J, Wertheimer JH, Hawkins M. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarc- tion: results of the Survival and Ventricular Enlargement Trial: the SAVE Investigators. N Engl J Med. 1992;327:669 677. doi: 10.1056/ NEJM199209033271001. 242. Jong P,Yusuf S, Rousseau MF, Ahn SA, Bangdiwala SI. Effect of enala- pril on 12-year survival and life expectancy in patients with left ventricu- lar systolic dysfunction: a follow-up study. Lancet. 2003;361:1843 1848. doi: 10.1016/S0140-6736(03)13501-5. 243. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions: the SOLVD Investigators. N Engl J Med. 1992;327:685 691. 244. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS): the CONSENSUS Trial Study Group. N Engl J Med. 1987;316:1429 1435. 245. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, Smith R, Dunkman WB, Loeb H, Wong M, Bhat G, Goldman S, Fletcher RD, Doherty J, Hughes V, Carson P, Cintron G, Shabetai R, Haakenson C. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991;325:303 310. doi: 10.1056/NEJM199108013250502. 246. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure: the SOLVD Investigators. N Engl J Med. 1991;325:293 302. 247. Verdecchia P, Sleight P, Mancia G, Fagard R, Trimarco B, Schmieder RE, Kim JH, Jennings G, Jansky P, Chen JH, Liu L, Gao P, Probstfield J, Teo K, Yusuf S; ONTARGET/TRANSCENT Investigators. Effects of telmisartan, ramipril, and their combination on left ventricular hyper- trophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease. Circulation. 2009;120:1380 1389. doi: 10.1161/CIRCULATIONAHA.109.865774. 248. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Yusuf S, Pocock S; CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003;362:759 766. 249. Pfeffer MA, McMurray JJ,Velazquez EJ, Rouleau JL, K ber L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM; Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ven- tricular dysfunction, or both. N Engl J Med. 2003;349:1893 1906. doi: 10.1056/NEJMoa032292. 250. Cohn JN, Tognoni G; Valsartan Heart Failure Trial Investigators. A ran- domized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667 1675. doi: 10.1056/ NEJMoa010713. 251. Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, Ostergren J, Pfeffer MA, Swedberg K; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin- converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet. 2003;362:772 776. doi: 10.1016/S0140-6736(03)14284-5. 252. McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, Olofsson B, Yusuf S, Pfeffer MA; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angioten- sin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet. 2003;362:767 771. doi: 10.1016/S0140-6736(03)14283-3. 253. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure: Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709 717. doi: 10.1056/ NEJM199909023411001. 254. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B; EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11 21. doi: 10.1056/NEJMoa1009492. 255. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, Daubert JP, Higgins SL, Brown MW, Andrews ML; Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implanta- tion of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877 883. doi: 10.1056/ NEJMoa013474. 256. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, Domanski M, Troutman C, Anderson J, Johnson G, McNulty SE, Clapp-Channing N, Davidson-Ray LD, Fraulo ES, Fishbein DP, Luceri RM, Ip JH; Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225 237. doi: 10.1056/NEJMoa043399. Kulik et al Secondary Prevention After CABG 959 257. Nanthakumar K, Epstein AE, Kay GN, Plumb VJ, Lee DS. Prophylactic implantable cardioverter-defibrillator therapy in patients with left ven- tricular systolic dysfunction: a pooled analysis of 10 primary preven- tion trials. J Am Coll Cardiol. 2004;44:2166 2172. doi: 10.1016/j. jacc.2004.08.054. 258. Bigger JT Jr. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery: Coronary Artery Bypass Graft (CABG) Patch Trial Investigators. N Engl J Med. 1997;337:1569 1575. doi: 10.1056/ NEJM199711273372201. 259. Namerow PB, Firth BR, Heywood GM, Windle JR, Parides MK. Quality-of-life six months after CABG surgery in patients randomized to ICD versus no ICD therapy: findings from the CABG Patch Trial. Pacing Clin Electrophysiol. 1999;22:1305 1313. 260. Epstein AE, DiMarco JP, Ellenbogen KA, Estes NA 3rd, Freedman RA, Gettes LS, Gillinov AM, Gregoratos G, Hammill SC, Hayes DL, Hlatky MA, Newby LK, Page RL, Schoenfeld MH, Silka MJ, Stevenson LW, Sweeney MO; American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines; Heart Rhythm Society. 2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation. 2013;127:e283 e352. doi: 10.1161/CIR.0b013e318276ce9b. 261. Every NR, Fahrenbruch CE, Hallstrom AP, Weaver WD, Cobb LA. Influence of coronary bypass surgery on subsequent outcome of patients resuscitated from out of hospital cardiac arrest. J Am Coll Cardiol. 1992;19:1435 1439. 262. Autschbach R, Falk V, Gonska BD, Dalichau H. The effect of coronary bypass graft surgery for the prevention of sudden cardiac death: recur- rent episodes after ICD implantation and review of literature. Pacing Clin Electrophysiol. 1994;17(pt 2):552 558. 263. Berntsen RF, Gunnes P, Lie M, Rasmussen K. Surgical revascularization in the treatment of ventricular tachycardia and fibrillation exposed by exercise-induced ischaemia. Eur Heart J. 1993;14:1297 1303. 264. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, Carson P, DiCarlo L, DeMets D, White BG, DeVries DW, Feldman AM; Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350:2140 2150. doi: 10.1056/ NEJMoa032423. 265. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, Tavazzi L; Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators. The effect of cardiac resynchro- nization on morbidity and mortality in heart failure. N Engl J Med. 2005;352:1539 1549. doi: 10.1056/NEJMoa050496. 266. Moss AJ, Hall WJ, Cannom DS, Klein H, Brown MW, Daubert JP, Estes NA 3rd, Foster E, Greenberg H, Higgins SL, Pfeffer MA, Solomon SD, Wilber D, Zareba W; MADIT-CRT Trial Investigators. Cardiac- resynchronization therapy for the prevention of heart-failure events. N Engl J Med. 2009;361:1329 1338. doi: 10.1056/NEJMoa0906431. 267. Tang AS, Wells GA, Talajic M, Arnold MO, Sheldon R, Connolly S, Hohnloser SH, Nichol G, Birnie DH, Sapp JL, Yee R, Healey JS, Rouleau JL; Resynchronization-Defibrillation for Ambulatory Heart Failure Trial Investigators. Cardiac-resynchronization therapy for mild- to-moderate heart failure. N Engl J Med. 2010;363:2385 2395. doi: 10.1056/NEJMoa1009540. 268. Kim YG, Park DW, Lee WS, Park GM, Sun BJ, Lee CH, Hwang KW, Cho SW, Kim YR, Song HG, Ahn JM, Kim WJ, Lee JY, Kang SJ, Lee SW, KimYH, Lee CW, Park SW, Han S, Jung SH, Choo SJ, Chung CH, Lee JW, Park SJ. Influence of diabetes mellitus on long-term (five-year) outcomes of drug-eluting stents and coronary artery bypass grafting for multivessel coronary revascularization. Am J Cardiol. 2012;109:1548 1557. doi: 10.1016/j.amjcard.2012.01.377. 269. American Diabetes Association. Standards of medical care in diabe- tes 2012. Diabetes Care. 2012;35(suppl 1):S11 S63. 270. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2012;35(suppl 1):S64 71. 271. International Expert Committee. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care. 2009;32:1327 1334. 272. Lazar HL, McDonnell M, Chipkin SR, Furnary AP, Engelman RM, Sadhu AR, Bridges CR, Haan CK, Svedjeholm R, Taegtmeyer H, Shemin RJ; Society of Thoracic Surgeons Blood Glucose Guideline Task Force. The Society of Thoracic Surgeons practice guideline series: blood glucose management during adult cardiac surgery. Ann Thorac Surg. 2009;87:663 669. doi: 10.1016/j.athoracsur.2008.11.011. 273. Frioud A, Comte-Perret S, Nguyen S, Berger MM, Ruchat P, Ruiz J. Blood glucose level on postoperative day 1 is predictive of adverse out- comes after cardiovascular surgery. Diabetes Metab. 2010;36:36 42. doi: 10.1016/j.diabet.2009.06.008. 274. Lazar HL, Chipkin SR, Fitzgerald CA, Bao Y, Cabral H, Apstein CS. Tight glycemic control in diabetic coronary artery bypass graft patients improves perioperative outcomes and decreases recurrent ischemic events. Circulation. 2004;109:1497 1502. doi: 10.1161/01. CIR.0000121747.71054.79. 275. Lazar HL, McDonnell MM, Chipkin S, Fitzgerald C, Bliss C, Cabral H. Effects of aggressive versus moderate glycemic control on clinical outcomes in diabetic coronary artery bypass graft patients. Ann Surg. 2011;254:458 463. doi: 10.1097/SLA.0b013e31822c5d78. 276. Desai SP, Henry LL, Holmes SD, Hunt SL, Martin CT, Hebsur S, Ad N. Strict versus liberal target range for perioperative glucose in patients undergoing coronary artery bypass grafting: a prospective randomized controlled trial. J Thorac Cardiovasc Surg. 2012;143:318 325. doi: 10.1016/j.jtcvs.2011.10.070. 277. Bhamidipati CM, LaPar DJ, Stukenborg GJ, Morrison CC, Kern JA, Kron IL, Ailawadi G. Superiority of moderate control of hyperglyce- mia to tight control in patients undergoing coronary artery bypass graft- ing. J Thorac Cardiovasc Surg. 2011;141:543 551. doi: 10.1016/j. jtcvs.2010.10.005. 278. Banning AP, Westaby S, Morice MC, Kappetein AP, Mohr FW, Berti S, Glauber M, Kellett MA, Kramer RS, Leadley K, Dawkins KD, Serruys PW. Diabetic and nondiabetic patients with left main and/or 3-vessel coronary artery disease: comparison of outcomes with cardiac surgery and paclitaxel-eluting stents. J Am Coll Cardiol. 2010;55:1067 1075. doi: 10.1016/j.jacc.2009.09.057. 279. Yilmaz MB, Guray Y, Guray U, Biyikoglu SF, Tandogan I, Korkmaz S. Metabolic syndrome increases the risk of significant coronary artery involvement in patients with peripheral artery disease. Coron Artery Dis. 2006;17:529 532. 280. Lorusso R, Pentiricci S, Raddino R, Scarabelli TM, Zambelli C, Villanacci V, Burattin A, Romanelli G, Casari S, Scelsi R, Giustina A. Influence of type 2 diabetes on functional and structural properties of coronary artery bypass conduits. Diabetes. 2003;52:2814 2820. 281. Lytle BW, Loop FD, Cosgrove DM, Ratliff NB, Easley K, Taylor PC. Long-term (5 to 12 years) serial studies of internal mammary artery and saphenous vein coronary bypass grafts. J Thorac Cardiovasc Surg. 1985;89:248 258. 282. Goldman S, Zadina K, Moritz T, Ovitt T, Sethi G, Copeland JG, Thottapurathu L, Krasnicka B, Ellis N, Anderson RJ, Henderson W; VA Cooperative Study Group #207/297/364. Long-term patency of saphenous vein and left internal mammary artery grafts after coronary artery bypass surgery: results from a Department of Veterans Affairs Cooperative Study. J Am Coll Cardiol. 2004;44:2149 2156. doi: 10.1016/j.jacc.2004.08.064. 283. Parang P, Arora R. Coronary vein graft disease: pathogenesis and pre- vention. Can J Cardiol. 2009;25:e57 e62. 284. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B; Diabetes Control and Complications Trial/ Epidemiology of Diabetes Interventions and Complications (DCCT/ EDIC) Study Research Group. Intensive diabetes treatment and car- diovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643 2653. doi: 10.1056/NEJMoa052187. 285. Effect of intensive blood-glucose control with metformin on com- plications in overweight patients with type 2 diabetes (UKPDS 34): UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:854 865. 286. Intensive blood-glucose control with sulphonylureas or insulin com- pared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33): UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:837 853. 287. Skyler JS, Bergenstal R, Bonow RO, Buse J, Deedwania P, Gale EA, Howard BV, Kirkman MS, Kosiborod M, Reaven P, Sherwin RS; American Diabetes Association; American College of Cardiology Foundation; American Heart Association. 